Results 121 to 130 of about 54,594 (319)

Effect of cell retention techniques in Komagataella phaffii lab‐scale continuous processes

Biotechnology Progress, EarlyView.
Abstract Perfusion technologies play a growing role in the implementation of continuous processes for biotherapeutics production in mammalian‐based manufacturing. However, their application to alternative production hosts is limited. Cell retention systems are of key importance for the efficiency of perfusion bioreactors.
Marina Y. Linova, Satish K. Kodiripaka, Edite Martins, Sobhana A. Sripada, Stefano Menegatti, John M. Woodley   +5 more
wiley   +1 more source

Homogeneous Bispecifics by Disulfide Bridging

Bioconjugate Chemistry, 2014
We report on a chemical platform to generate site-specific, homogeneous, antibody-antibody conjugates by targeting and bridging disulfide bonds. A bispecific antibody construct was produced in good yield through simple reduction and bridging of antibody fragment disulfide bonds, using a readily synthesized bis-dibromomaleimide cross-linker.
Hull, EA, Livanos, M, Miranda, E, Smith, ME, Chester, KA, Baker, JR   +5 more
openaire   +3 more sources

Enhancing CHO cell recombinant protein production using a perfusion‐directed host evolution approach

Biotechnology Progress, EarlyView.
Abstract Clonally derived cell lines generated from Chinese hamster ovary (CHO) cells encounter numerous stressors when cultured in high‐intensity perfusion bioreactors leading to poor process performance. To circumvent this, the ability of CHO cells to adapt to different culture environments was exploited. Here host cells were selected in the presence
Peter Amaya, Rajesh K. Mistry, Susie Sou, Sonja Hess, Bijay Khanal, Zayla Schaeffer, Jie Zhu, Lina Chakrabarti   +7 more
wiley   +1 more source

Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X

Research and Practice in Thrombosis and Haemostasis
Background: Persons with hemophilia A (HA) and inhibitors undergoing emicizumab prophylaxis require bypassing agents when breakthrough bleeding occurs.
Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami   +4 more
doaj   +1 more source

A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity [PDF]

, 2015
Zhiguo Chen, Wei Xie, Desmond Omane Acheampong, Menghuai Xu, Hua He, Mengqi Yang, Chenchen Li, Chen Luo, Min Wang, Juan Zhang   +9 more
openalex   +1 more source

Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021

International Journal of Cancer, EarlyView.
What's New? Liver metastasis is an indicator of life expectancy for patients with advanced uveal melanoma (UM). Data on anticipated survival time following the diagnosis of liver metastasis, however, is lacking. The present study analyzed long‐term survival among UM patients who lived three or more years after liver metastases were diagnosed.
Jona Laukhuf, Lisa Wiens, Gerd Grözinger, Helmut Dittmann, Karolin Thiel, Ulrike Leiter, Teresa Amaral, Lena Nanz, Lukas Flatz, Markus Reitmajer, Andrea Forschner   +10 more
wiley   +1 more source

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

mAbs
The development of bispecific antibodies that bind at least two different targets relies on bringing together multiple binding domains with different binding properties and biophysical characteristics to produce a drug-like therapeutic.
Michael Mullin, James McClory, Winston Haynes, Justin Grace, Nathan Robertson, Gino van Heeke   +5 more
doaj   +1 more source

Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies

, 2020
Brian H. Santich, Jeong A Park, Hoa Tran, Hong-Fen Guo, Morgan Huse, Nai‐Kong V. Cheung   +5 more
openalex   +2 more sources

Global Burden of Hematologic Malignancies From 1990 to 2021 With Projections to 2030: A Systematic Analysis for the Global Burden of Disease Study 2021

iNew Medicine, EarlyView.
ABSTRACT This study aimed to comprehensively analyze the epidemiological trends and global burden of hematologic malignancies (HM) from 1990 to 2021 and to project trends up to the year 2030. Using data from the Global Burden of Disease (GBD) Study 2021, we analyzed the age‐standardized rates (ASRs) and the trends of HM from 1990 to 2021. Decomposition
Ziyuan Shen, Linyu Huang, Xing Xing, Danting Zhang, Guoqi Cai, Wei Sang   +5 more
wiley   +1 more source

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release

mAbs
T cell engagers (TCEs) are becoming an integral class of biological therapeutic owing to their highly potent ability to eradicate cancer cells. Nevertheless, the widespread utility of classical CD3-targeted TCEs has been limited by narrow therapeutic ...
John S. Schardt, Even Walseng, Kim Le, Chunning Yang, Pooja Shah, Ying Fu, Kausar Alam, Cathryn R. Kelton, Yu Gu, Fengying Huang, Jia Lin, Wenhai Liu, Andrew Dippel, Hanzhi Zhang, Kathy Mulgrew, Stacy Pryts, Vijaykumar Chennupati, Hung-Chang Chen, Jessica Denham, Xiaoru Chen, Pallab Pradhan, Yuling Wu, Colin Hardman, Chihao Zhao, Michael Kierny, Yang Song, Simon J. Dovedi, Saso Cemerski, Yariv Mazor   +28 more
doaj   +1 more source